Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) were down 5.9% during mid-day trading on Tuesday . The company traded as low as $0.33 and last traded at $0.36. Approximately 745,149 shares changed hands during trading, a decline of 72% from the average daily volume of 2,673,511 shares. The stock had previously closed at $0.34.
Several equities analysts have weighed in on the company. Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine raised Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday. Finally, B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.
The company has a market cap of $12.56, a PE ratio of -0.40 and a beta of 3.56.
In other Cytori Therapeutics news, major shareholder Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares during the period. Sabby Management LLC boosted its stake in shares of Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares during the period. Finally, Perkins Capital Management Inc. boosted its stake in shares of Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares during the period. Institutional investors and hedge funds own 10.82% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/06/cytori-therapeutics-cytx-stock-price-down-5-9.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.